Vaxzevria (previously COVID-19 Vaccine AstraZeneca) Europeiska unionen - kroatiska - EMA (European Medicines Agency)

vaxzevria (previously covid-19 vaccine astrazeneca)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - cjepiva - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Vyepti Europeiska unionen - kroatiska - EMA (European Medicines Agency)

vyepti

h. lundbeck a/s - eptinezumab - migrena poremećaja - analgetici - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

VITAMIN C 500 mg/5 mL rastvor za injekciju Bosnien och Hercegovina - kroatiska - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

vitamin c 500 mg/5 ml rastvor za injekciju

galenika d.o.o. - askorbinska kiselina - rastvor za injekciju - 500 mg/5 ml - 5 ml rastvora za injekciju sadrži: 500 mg askorbinska kiselina

Vydura Europeiska unionen - kroatiska - EMA (European Medicines Agency)

vydura

pfizer europe ma eeig  - rimegepant - migrena poremećaja - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

VITAMIN C GALENIKA 500 mg/5 mL rastvor za injekciju Bosnien och Hercegovina - kroatiska - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

vitamin c galenika 500 mg/5 ml rastvor za injekciju

galenika d.o.o. - askorbinska kiselina - rastvor za injekciju - 500 mg/5 ml - 5 ml rastvora za injekciju sadrži: 500 mg askorbinske kiseline

POLINOL 25 mg/1 tableta+ 25 mg/1 tableta+ 25 mg/1 tableta tableta Bosnien och Hercegovina - kroatiska - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

polinol 25 mg/1 tableta+ 25 mg/1 tableta+ 25 mg/1 tableta tableta

alpen pharma d.o.o. - cardiospermum, galfimia Глаука diehl. d3, Д4 люффы operculata Трит. - tableta - 25 mg/1 tableta+ 25 mg/1 tableta+ 25 mg/1 tableta - jedna tableta sadrži: 25 mg luffa operculata trit. d4 25 mg galphimia glauca trit. d3 25 mg cardiospermum trit. d3

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Europeiska unionen - kroatiska - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Osan 40 mg tablete Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

osan 40 mg tablete

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb - telmisartanum - tableta - 40 mg - urbroj: jedna tableta sadrži 40 mg telmisartana

Osan 80 mg tablete Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

osan 80 mg tablete

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb - telmisartanum - tableta - 80 mg - urbroj: jedna tableta sadrži 80 mg telmisartana

TOLURA 20 mg/1 tableta tableta Bosnien och Hercegovina - kroatiska - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

tolura 20 mg/1 tableta tableta

krka farma d.o.o. sarajevo - telmisartan - tableta - 20 mg/1 tableta - 1 tableta sadrži: 20 mg telmisartana